An article posted on AuntMinnie.com on April 14, 2005 (Iodixanol more cost-effective than iohexol in renal angiography) incorrectly stated that a recent study found iso-osmolar contrast agents to be more cost-effective than low-osmolar agents in renal angiography. In fact, the study compared one iso-osmolar agent, iodixanol, to a low-osmolar agent, iohexol, and did not draw conclusions on the relative cost-effectiveness of all iso-osmolar versus low-osmolar agents.
In addition, the story incorrectly attributed the source data on the incidence of contrast-induced nephropathy in high-risk patient groups like diabetics with renal impairment. The correct source was the original Nephrotoxic Effects in High-Risk Patients Undergoing Angiography (NEPHRIC) study.
In an article on Nucletron's new OncoSmart product on April 18, 2005 ("Nucletron gets FDA OK for OncoSmart", we incorrectly stated that the product is used to place brachytherapy seeds. The system is actually used for preoperative endorectal high-dose rate (HDR) and pulsed-dose rate (PDR) brachytherapy.
